CORCEPT THERAPEUTICS INC (CORT) Fundamental Analysis & Valuation

NASDAQ:CORT • US2183521028

Current stock price

43.68 USD
+0.38 (+0.88%)
At close:
43.68 USD
0 (0%)
After Hours:

This CORT fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

8

1. CORT Profitability Analysis

1.1 Basic Checks

  • In the past year CORT was profitable.
  • CORT had a positive operating cash flow in the past year.
  • In the past 5 years CORT has always been profitable.
  • In the past 5 years CORT always reported a positive cash flow from operatings.
CORT Yearly Net Income VS EBIT VS OCF VS FCFCORT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M

1.2 Ratios

  • The Return On Assets of CORT (11.91%) is better than 92.67% of its industry peers.
  • CORT has a better Return On Equity (15.38%) than 88.48% of its industry peers.
  • CORT has a better Return On Invested Capital (5.84%) than 82.72% of its industry peers.
  • Measured over the past 3 years, the Average Return On Invested Capital for CORT is in line with the industry average of 13.10%.
  • The 3 year average ROIC (13.70%) for CORT is well above the current ROIC(5.84%). The reason for the recent decline needs to be investigated.
Industry RankSector Rank
ROA 11.91%
ROE 15.38%
ROIC 5.84%
ROA(3y)15.26%
ROA(5y)17.94%
ROE(3y)19.04%
ROE(5y)21.45%
ROIC(3y)13.7%
ROIC(5y)17.86%
CORT Yearly ROA, ROE, ROICCORT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20 40 60

1.3 Margins

  • CORT has a better Profit Margin (13.09%) than 86.39% of its industry peers.
  • In the last couple of years the Profit Margin of CORT has declined.
  • With an excellent Operating Margin value of 5.88%, CORT belongs to the best of the industry, outperforming 80.63% of the companies in the same industry.
  • In the last couple of years the Operating Margin of CORT has declined.
  • CORT has a Gross Margin of 98.30%. This is amongst the best in the industry. CORT outperforms 97.38% of its industry peers.
  • In the last couple of years the Gross Margin of CORT has remained more or less at the same level.
Industry RankSector Rank
OM 5.88%
PM (TTM) 13.09%
GM 98.3%
OM growth 3Y-40.56%
OM growth 5Y-30.48%
PM growth 3Y-19.65%
PM growth 5Y-15.26%
GM growth 3Y-0.12%
GM growth 5Y-0.02%
CORT Yearly Profit, Operating, Gross MarginsCORT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20 40 60 80

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

8

2. CORT Health Analysis

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so CORT is still creating some value.
  • Compared to 1 year ago, CORT has more shares outstanding
  • Compared to 5 years ago, CORT has less shares outstanding
  • There is no outstanding debt for CORT. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
CORT Yearly Shares OutstandingCORT Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M 100M
CORT Yearly Total Debt VS Total AssetsCORT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M

2.2 Solvency

  • An Altman-Z score of 17.26 indicates that CORT is not in any danger for bankruptcy at the moment.
  • CORT has a better Altman-Z score (17.26) than 87.96% of its industry peers.
  • CORT has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z 17.26
ROIC/WACC0.63
WACC9.34%
CORT Yearly LT Debt VS Equity VS FCFCORT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M

2.3 Liquidity

  • A Current Ratio of 2.92 indicates that CORT has no problem at all paying its short term obligations.
  • The Current ratio of CORT (2.92) is comparable to the rest of the industry.
  • CORT has a Quick Ratio of 2.85. This indicates that CORT is financially healthy and has no problem in meeting its short term obligations.
  • Looking at the Quick ratio, with a value of 2.85, CORT is in line with its industry, outperforming 52.36% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 2.92
Quick Ratio 2.85
CORT Yearly Current Assets VS Current LiabilitesCORT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M 400M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

7

3. CORT Growth Analysis

3.1 Past

  • CORT shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -33.87%.
  • Measured over the past years, CORT shows a decrease in Earnings Per Share. The EPS has been decreasing by -0.72% on average per year.
  • The Revenue has grown by 12.79% in the past year. This is quite good.
  • Measured over the past years, CORT shows a quite strong growth in Revenue. The Revenue has been growing by 16.56% on average per year.
EPS 1Y (TTM)-33.87%
EPS 3Y-2.33%
EPS 5Y-0.72%
EPS Q2Q%-23.08%
Revenue 1Y (TTM)12.79%
Revenue growth 3Y23.74%
Revenue growth 5Y16.56%
Sales Q2Q%11.12%

3.2 Future

  • CORT is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 59.90% yearly.
  • CORT is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 22.39% yearly.
EPS Next Y-33.82%
EPS Next 2Y32.83%
EPS Next 3Y56.35%
EPS Next 5Y59.9%
Revenue Next Year15.59%
Revenue Next 2Y23.08%
Revenue Next 3Y22.35%
Revenue Next 5Y22.39%

3.3 Evolution

  • The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
CORT Yearly Revenue VS EstimatesCORT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 500M 1B 1.5B 2B 2.5B
CORT Yearly EPS VS EstimatesCORT Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 0 2 4 6 8 10

More info and screens

Find the best growth stocksShow best growing peers

5

4. CORT Valuation Analysis

4.1 Price/Earnings Ratio

  • CORT is valuated quite expensively with a Price/Earnings ratio of 53.27.
  • Based on the Price/Earnings ratio, CORT is valued a bit cheaper than 78.01% of the companies in the same industry.
  • CORT is valuated expensively when we compare the Price/Earnings ratio to 27.18, which is the current average of the S&P500 Index.
  • Based on the Price/Forward Earnings ratio of 80.50, the valuation of CORT can be described as expensive.
  • CORT's Price/Forward Earnings ratio is a bit cheaper when compared to the industry. CORT is cheaper than 69.63% of the companies in the same industry.
  • Compared to an average S&P500 Price/Forward Earnings ratio of 37.96, CORT is valued quite expensively.
Industry RankSector Rank
PE 53.27
Fwd PE 80.5
CORT Price Earnings VS Forward Price EarningsCORT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60 80

4.2 Price Multiples

  • Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of CORT indicates a somewhat cheap valuation: CORT is cheaper than 75.92% of the companies listed in the same industry.
  • Compared to the rest of the industry, the Price/Free Cash Flow ratio of CORT indicates a rather cheap valuation: CORT is cheaper than 81.15% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF 32.77
EV/EBITDA 86.44
CORT Per share dataCORT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 2 4 6

4.3 Compensation for Growth

  • The excellent profitability rating of CORT may justify a higher PE ratio.
  • CORT's earnings are expected to grow with 56.35% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y32.83%
EPS Next 3Y56.35%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. CORT Dividend Analysis

5.1 Amount

  • CORT does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

CORT Fundamentals: All Metrics, Ratios and Statistics

CORCEPT THERAPEUTICS INC

NASDAQ:CORT (4/14/2026, 4:10:05 PM)

After market: 43.68 0 (0%)

43.68

+0.38 (+0.88%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)02-24
Earnings (Next)05-06
Inst Owners72.81%
Inst Owner Change-0.1%
Ins Owners6.65%
Ins Owner Change1.52%
Market Cap4.65B
Revenue(TTM)761.41M
Net Income(TTM)99.65M
Analysts78.33
Price Target68.75 (57.39%)
Short Float %13.26%
Short Ratio6.53
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-9.22%
Min EPS beat(2)-34.64%
Max EPS beat(2)16.19%
EPS beat(4)3
Avg EPS beat(4)12.54%
Min EPS beat(4)-34.64%
Max EPS beat(4)51.63%
EPS beat(8)6
Avg EPS beat(8)12.54%
EPS beat(12)9
Avg EPS beat(12)13.9%
EPS beat(16)11
Avg EPS beat(16)8.82%
Revenue beat(2)0
Avg Revenue beat(2)-14.56%
Min Revenue beat(2)-22.27%
Max Revenue beat(2)-6.85%
Revenue beat(4)0
Avg Revenue beat(4)-11.72%
Min Revenue beat(4)-22.27%
Max Revenue beat(4)-4.4%
Revenue beat(8)3
Avg Revenue beat(8)-5.96%
Revenue beat(12)6
Avg Revenue beat(12)-3.32%
Revenue beat(16)7
Avg Revenue beat(16)-3.6%
PT rev (1m)-19.76%
PT rev (3m)-47%
EPS NQ rev (1m)0%
EPS NQ rev (3m)78.18%
EPS NY rev (1m)-34.32%
EPS NY rev (3m)-50.63%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-19.18%
Revenue NY rev (1m)-2.99%
Revenue NY rev (3m)-20%
Valuation
Industry RankSector Rank
PE 53.27
Fwd PE 80.5
P/S 6.1
P/FCF 32.77
P/OCF 32.72
P/B 7.17
P/tB 7.17
EV/EBITDA 86.44
EPS(TTM)0.82
EY1.88%
EPS(NY)0.54
Fwd EY1.24%
FCF(TTM)1.33
FCFY3.05%
OCF(TTM)1.33
OCFY3.06%
SpS7.16
BVpS6.09
TBVpS6.09
PEG (NY)N/A
PEG (5Y)N/A
Graham Number10.6
Profitability
Industry RankSector Rank
ROA 11.91%
ROE 15.38%
ROCE 6.68%
ROIC 5.84%
ROICexc 13.36%
ROICexgc 13.36%
OM 5.88%
PM (TTM) 13.09%
GM 98.3%
FCFM 18.62%
ROA(3y)15.26%
ROA(5y)17.94%
ROE(3y)19.04%
ROE(5y)21.45%
ROIC(3y)13.7%
ROIC(5y)17.86%
ROICexc(3y)38.16%
ROICexc(5y)61.97%
ROICexgc(3y)38.16%
ROICexgc(5y)61.97%
ROCE(3y)15.67%
ROCE(5y)20.43%
ROICexgc growth 3Y-52.44%
ROICexgc growth 5Y-36.96%
ROICexc growth 3Y-52.44%
ROICexc growth 5Y-36.96%
OM growth 3Y-40.56%
OM growth 5Y-30.48%
PM growth 3Y-19.65%
PM growth 5Y-15.26%
GM growth 3Y-0.12%
GM growth 5Y-0.02%
F-Score6
Asset Turnover0.91
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA 0
Cap/Depr 18.36%
Cap/Sales 0.03%
Interest Coverage 250
Cash Conversion 309.05%
Profit Quality 142.28%
Current Ratio 2.92
Quick Ratio 2.85
Altman-Z 17.26
F-Score6
WACC9.34%
ROIC/WACC0.63
Cap/Depr(3y)101.64%
Cap/Depr(5y)80.07%
Cap/Sales(3y)0.13%
Cap/Sales(5y)0.12%
Profit Quality(3y)133.58%
Profit Quality(5y)133.55%
High Growth Momentum
Growth
EPS 1Y (TTM)-33.87%
EPS 3Y-2.33%
EPS 5Y-0.72%
EPS Q2Q%-23.08%
EPS Next Y-33.82%
EPS Next 2Y32.83%
EPS Next 3Y56.35%
EPS Next 5Y59.9%
Revenue 1Y (TTM)12.79%
Revenue growth 3Y23.74%
Revenue growth 5Y16.56%
Sales Q2Q%11.12%
Revenue Next Year15.59%
Revenue Next 2Y23.08%
Revenue Next 3Y22.35%
Revenue Next 5Y22.39%
EBIT growth 1Y-67.29%
EBIT growth 3Y-26.45%
EBIT growth 5Y-18.97%
EBIT Next Year-2.52%
EBIT Next 3Y47.49%
EBIT Next 5Y38.71%
FCF growth 1Y-27.71%
FCF growth 3Y5.75%
FCF growth 5Y-1.23%
OCF growth 1Y-28.39%
OCF growth 3Y5.68%
OCF growth 5Y-1.35%

CORCEPT THERAPEUTICS INC / CORT Fundamental Analysis FAQ

What is the ChartMill fundamental rating of CORCEPT THERAPEUTICS INC (CORT) stock?

ChartMill assigns a fundamental rating of 7 / 10 to CORT.


What is the valuation status of CORCEPT THERAPEUTICS INC (CORT) stock?

ChartMill assigns a valuation rating of 5 / 10 to CORCEPT THERAPEUTICS INC (CORT). This can be considered as Fairly Valued.


What is the profitability of CORT stock?

CORCEPT THERAPEUTICS INC (CORT) has a profitability rating of 8 / 10.


Can you provide the financial health for CORT stock?

The financial health rating of CORCEPT THERAPEUTICS INC (CORT) is 8 / 10.